Clover Health Investments Crop. ($CLOV) Stock Forecast: Up 5.3% Today

What is Clover Health Investments Crop.?

Clover Health Investments Corp. (CLOV) is a company listed on the NASDAQ, known for its innovative healthcare solutions and services. The overall market sentiment today was bullish.

Why is Clover Health Investments Crop. going up?

CLOV stock is up 5.3% on Jun 26, 2026 15:11

• CLOV experienced a strong bullish movement likely due to positive analyst forecasts and financial actuals exceeding expectations.
• The detailed overview of CLOV's financial performance and upcoming earnings report dates may have instilled confidence in investors, driving the stock price higher.
• The market capitalization and revenue figures could have contributed to the positive momentum of CLOV's stock.

CLOV Price Chart

CLOV Technical Analysis

CLOV News

Clover Health Investments Corp. Class A Actuals & Estimates (NASDAQ:CLOV)

This article provides an overview of Clover Health Investments Corp. (NASDAQ: CLOV), detailing its financial actuals and estimates. It covers the company's current stock price, historical highs and lows, market capitalization, and volatility. Additionally, it includes analysts' forecasts, recent earnings, revenue figures, and upcoming earnings report dates.

https://www.tradingview.com/symbols/NASDAQ-CLOV/forecast-actuals-and-estimates/

Trending Today

McCormick & Company Incorporated ($MKC) Stock Forecast: Up 5.5% Today

Stryker Corporation ($SYK) Stock Forecast: Up 5.4% Today

Salesforce.com Inc ($CRM) Stock Forecast: Up 5.3% Today

Applied Materials Inc. ($AMAT) Stock Forecast: Down 6.7% Today

Cisco Systems Inc. ($CSCO) Stock Forecast: Down 5.0% Today

Fastly Inc. ($FSLY) Stock Forecast: Up 6.0% Today

Robinhood Inc. ($HOOD) Stock Forecast: Up 5.9% Today

Shopify Inc. Class A Subordinate ($SHOP) Stock Forecast: Up 5.4% Today

Caterpillar Inc. ($CAT) Stock Forecast: Down 5.1% Today

Lam Research Corporation ($LRCX) Stock Forecast: Down 5.3% Today

Clover Health Investments Crop. Price History

19.04.2026 - CLOV Stock was up 5.0%

• The interim CFO of Clover Health, Joseph Clay, had a portion of his RSUs withheld for tax obligations, suggesting positive sentiments about the company's future outlook.
• Fidelity Investments' SEC filing to sell a significant number of shares had a neutral impact on the market, indicating that this action might not be perceived negatively by market participants.
• Despite CEO Brady Patrick Priest selling a substantial amount of shares, analysts continue to forecast profitability for the company this year, potentially bolstering investor confidence.
• The CEO's insider selling of shares, though initially causing some negativity, did not deter investors, potentially highlighting a focus on the company's growth prospects.

15.04.2026 - CLOV Stock was down 5.3%

• The decrease in CLOV's stock price could be linked to the CEO, Brady Patrick Priest, selling a considerable number of shares, potentially indicating uncertainties or lacking confidence within the company.
• Furthermore, the insider selling disclosed in Form 4 filings by both CEO Brady Patrick Priest and CEO Andrew Toy may have triggered concerns among investors, resulting in diminished market trust and a subsequent drop in the stock value.
• Despite analysts forecasting profitability for the ongoing year, the stock's perception of being slightly overvalued, as highlighted in InvestingPro's analysis, might have also played a role in fostering negative sentiment and downward pressure on CLOV's shares.

16.05.2026 - CLOV Stock was up 6.6%

• The bullish movement in CLOV's stock could be attributed to the routine selling of vested shares by the CEO, Jamie Reynoso, which may have positively impacted investor confidence.
• The filing of Form 144 for the sale of vested shares and the CEO's strategic selling under a pre-arranged trading plan could have been perceived as a normal part of executive compensation and not a cause for concern.
• Despite concerns about the stock being overvalued, the CEO's sale of shares at a weighted average price and retaining a significant portion of her holdings could have reassured investors about the company's stability and growth potential.
• Overall, the combination of routine filings, strategic selling by the CEO, and the company's underlying business fundamentals may have contributed to the bullish movement in CLOV's stock today.

18.05.2026 - CLOV Stock was up 5.4%

• Today's rise in Clover Health's stock price reflects positive market sentiment fueled by its strong performance so far in 2021 and the recent upgrade in its Medicare star rating.
• The sale of shares by Clover Health's VP of Finance and Controller to address tax obligations resulting from vested restricted stock units raised initial concerns. However, since these transactions were mandatory rather than optional, they are perceived as part of routine financial management rather than an indication of negative internal sentiments.
• The overall surge in Clover Health's stock value today is likely a result of its robust financial performance, positive industry acknowledgment, and routine financial activities by company executives.
• The market appears to be responding positively to Clover Health's recent achievements and financial decisions, leading to an increase in the stock price amid an optimistic industry outlook.

26.05.2026 - CLOV Stock was up 5.3%

• CLOV experienced a strong bullish movement likely due to positive analyst forecasts and financial actuals exceeding expectations.
• The detailed overview of CLOV's financial performance and upcoming earnings report dates may have instilled confidence in investors, driving the stock price higher.
• The market capitalization and revenue figures could have contributed to the positive momentum of CLOV's stock.

17.05.2026 - CLOV Stock was down 5.5%

• Today, CLOV faced a decline in the market, which is potentially attributable to insider selling activities:
• CEO Jamie Reynoso and Chief Legal Officer Karen Soares both participated in "sell to cover" transactions to meet tax obligations related to vested restricted stock units.
• Despite being routine and non-discretionary, these insider sales may have influenced a pessimistic investor sentiment, exerting downward pressure on the stock price.
• Although CLOV had positive developments such as the upgraded Medicare star rating and impressive financial performance, the selling activities of key executives might have weighed down on the stock, resulting in today's bearish trend.

03.05.2026 - CLOV Stock was down 5.9%

• Today's downward movement in CLOV stock can be linked to several factors:
• A class action lawsuit alleging false and misleading statements and the withholding of vital information has potentially shaken investor confidence, prompting a sell-off.
• CEO Conrad Wai engaging in significant insider selling of company stock near its 52-week high could have indicated doubt about the company's future prospects.
• Despite the insider sales, Conrad Wai still holds a substantial stake in the company, raising concerns about potential future sales impacting the stock.
• Mixed Q1 2026 earnings were reported, with revenue exceeding forecasts but EPS falling short, potentially fueling negative sentiment around the stock.

02.05.2026 - CLOV Stock was down 5.0%

• The decline in CLOV stock may be linked to the CEO, Conrad Wai, selling a substantial amount of company stock, totaling $879k. This noteworthy insider selling activity could have sparked concerns among investors regarding the company's future prospects.
• The sale of 220,426 shares by the CEO, particularly when the stock was near its 52-week high, might have indicated to investors that insiders perceive the stock as possibly overvalued.
• Furthermore, the mixed Q1 2026 earnings report, where revenue surpassed expectations but EPS fell short, could have also played a role in the negative sentiment surrounding the stock. Investors may have responded unfavorably to the earnings shortfall despite the strong revenue performance.

29.04.2026 - CLOV Stock was down 5.6%

• Insider selling: A notable planned sale of shares by a company officer potentially conveyed doubts about the company's future, possibly influencing investor pessimism.
• Rule 10b5-1 trading plan: The implementation of the sale through a pre-arranged trading arrangement might have reinforced negative market perceptions, suggesting a deliberate strategy to divest shares.
• Market reaction: Investors likely viewed the insider selling as a warning sign, prompting a sell-off of CLOV stock and contributing to the day's downward trend.

14.04.2026 - CLOV Stock was up 7.5%

• The bullish movement in CLOV's stock price today may have been influenced by CEO Brady Patrick Priest's sale of shares, which could have boosted investor confidence in the company's future.
• Analysts' positive predictions of profitability for the current year might have contributed to the upward trend in CLOV's stock price, despite concerns about its valuation.
• The recent insider selling of shares by CEO Priest, disclosed in a Form 4 filing, initially raised concerns of insider trading but the market focus appears to have shifted towards the company's positive outlook.
• CEO Andrew Toy's routine share withholding transaction for tax purposes did not seem to have a significant impact on CLOV's market performance today, with investors likely more swayed by profitability forecasts and CEO Priest's share sale.

09.05.2026 - CLOV Stock was up 8.9%

• The bullish movement in CLOV's stock price could be attributed to investors' optimism or positive sentiment surrounding the company despite the ongoing legal challenges.
• The reminders and deadlines for investors to join the class action lawsuits may have already been factored into the stock price, leading to a less significant impact on the market movement.
• Investors may be focusing more on the potential growth prospects and technological innovations of Clover Health rather than the legal issues.
• It's possible that some traders are viewing the current legal challenges as temporary hurdles for the company, leading to increased buying interest and driving the stock price higher.

12.05.2026 - CLOV Stock was down 5.8%

• Today's decline in CLOV's stock price could be linked to the significant sale of CLOV common stock by CEO Jamie Reynoso. This sale may have raised concerns among investors regarding the company's future outlook.
• The disposal of 7,289 shares by Reynoso, although a minor portion of her total holdings, might have indicated skepticism about the current valuation of the stock.
• Furthermore, the analysis suggesting that the stock is presently overpriced could have intensified the selling pressure and contributed to the downward movement.
• Investors could view this insider transaction as a warning sign, fostering pessimism towards CLOV and pushing its stock price downward.